Back to Screener

Healthcare

Aileron Therapeutics, Inc.(ALRN)

Live Price

Offline

$2.11

+9.33% today

1Y Change

Window

No data

Market Cap
$45.72M
Revenue Growth
0.0%
EPS Growth
+44.2%
Dividend Yield
0.0%
No coverage

Historical coverage is still loading

We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.

No price data

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Aileron Therapeutics, Inc. (ALRN) is a Healthcare stock with a market cap of $45.72M. The stock last traded around $2.11. Baseline metrics include revenue growth of 0.0%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +44.2%, free cash flow +13.1% with operating margin 0.0% and ROIC -120.3%. Stock Foundry combines ALRN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2025 was reported on Nov 12, 2025, but the surprise data is still limited.

The setup is mixed rather than one-directional

Revenue is 0.0% and EPS is +44.2%, while operating margin sits near 0.0%.

Benchmark Edge

ALRN vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ALRN

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ALRN Max Drawdown

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ALRN and SPY.

Calendar-year return history is still loading or unavailable.
AI

Company Overview

Aileron Therapeutics, Inc.

Last Updated
May 7, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
Price/Book
1.5

Growth

Revenue
0.0%
EPS
+44.2%
Free Cash Flow
+13.1%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-281.0%
ROIC
-120.3%

Balance Sheet

Debt/Equity
Current Ratio
0.70

Earnings Reports

📅 Last reportedNov 12, 2025
PeriodB/MEPSEPS ΔRevenueRev Δ
Nov 12, 25
-0.21
Est
Est
Aug 12, 25
-282.05
Est
Est
Nov 14, 24
-0.27
Est -0.25
-8.0%
Est
Aug 14, 24
-0.45
Est -0.25
-80.0%
Est
Apr 15, 24
-1.54
Est -0.14
-1000.0%
Est
Mar 25, 24
-1.54
Est -0.16
-862.5%
134.0B
Est
Oct 13, 23
-0.40
Est -0.20
-100.0%
Est
Aug 11, 23
-0.39
Est -0.40
+2.5%
Est
May 8, 23
-0.82
Est -0.86
+4.7%
Est
Mar 20, 23
-1.02
Est -1.34
+23.9%
Est
Nov 1, 22
-1.40
Est -1.60
+12.5%
Est
Aug 15, 22
-1.80
Est -1.80
0.0%
Est
May 5, 22
-1.80
Est -1.60
-12.5%
Est
Mar 28, 22
-1.60
Est -1.60
0.0%
Est
Nov 12, 21
-1.40
Est -1.40
0.0%
Est
Aug 11, 21
-1.20
Est -1.40
+14.3%
Est

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.